Study of the enhanced anticancer efficacy of gambogic acid on Capan-1 pancreatic cancer cells when mediated via magnetic Fe$_3$O$_4$ nanoparticles

Cailian Wang$^{1,*}$
Haijun Zhang$^{1,*}$
Baoan Chen$^2$
Haitao Yin$^1$
Wenwen Wang$^1$

$^1$Department of Oncology, Zhongda Hospital, Medical School, Southeast University, Nanjing, People’s Republic of China; $^2$Department of Hematology, Zhongda Hospital, Medical School, Southeast University, Nanjing, People’s Republic of China

*These authors contributed equally to this work

Background: Gambogic acid (GA), a potent anticancer agent, is limited in clinical administration due to its poor water solubility. The aim of this study was to explore a drug delivery system based on magnetic Fe$_3$O$_4$ nanoparticles (MNP-Fe$_3$O$_4$) conjugated with GA to increase water solubility of the drug and enhance its chemotherapeutic efficiency for pancreatic cancer.

Methods: GA was conjugated with the MNP-Fe$_3$O$_4$ colloidal suspension by mechanical absorption polymerization to construct GA-loaded MNP-Fe$_3$O$_4$, which acted as a drug delivery system.

Results: Combination therapy with GA and MNP-Fe$_3$O$_4$ induced remarkable improvement in anticancer activity, which was demonstrated by optical microscopic observations, MTT assay, and nuclear DAPI staining. Furthermore, the possible signaling pathway was explored by Western blot. In Capan-1 pancreatic cancer cells, our observations demonstrated that this strategy could enhance potential anticancer efficiency by inducing apoptosis. The mechanisms of the synergistic effect may be due to reducing protein expression of Bcl-2 and enhancing that of Bax, caspase 9, and caspase 3.

Conclusion: These findings demonstrate that a combination of GA and MNPs-Fe$_3$O$_4$ represents a promising approach to the treatment of pancreatic cancer.

Keywords: gambogic acid, pancreatic cancer, magnetic nanoparticles, drug delivery system, apoptosis

Introduction
With one of the highest mortality-to-incidence ratios, pancreatic cancer is the eighth leading cause of cancer-related death in men worldwide and the ninth in women.$^1$ The disease is usually detected at an advanced stage, carries a poor prognosis regardless of treatment, and is associated with debilitating symptoms. After initial diagnosis, most patients have a median survival with treatment of about 6 months.$^1$ Even in cases where the cancer is diagnosed at an early resectable stage, 5-year survival is still only 22%.$^2$ Advances in treating pancreatic cancer have been few and modest. Pancreatic cancer is well recognized as an extremely challenging disease on multiple fronts, and the use of chemotherapy has been shown to improve survival.$^3$ There is now more emphasis on early chemotherapy in locally advanced pancreatic cancer and combination chemotherapy in metastatic disease.$^1$

Gambogic acid (GA), a natural compound extracted from gamboges, has recently been identified as a potent anticancer agent. Recent studies have shown that GA can inhibit growth of a wide variety of tumor cells, including hepatoma, pulmonary carcinoma, gastric cancer, and breast cancer.$^4$-$^7$ However, little is known about the effect
of GA in pancreatic cancer. In addition, the therapeutic effect of GA is limited due to low water solubility. Therefore, efforts should be made to develop new delivery techniques to increase water solubility which could alter its biodistribution, enhance its deposition in tumor sites, and improve its therapeutic efficacy.8

Various types of nanosized drug carriers, such as liposomes, polymeric micelles, dendrimers, superparamagnetic iron oxide crystals, semiconductor nanomaterials, and colloidal gold, have been investigated in cancer therapy in order to minimize the side effects of anticancer therapy, improve water solubility of drugs, and enhance the antitumoral efficacy of targeted therapies.9,10 The most promising materials are magnetic nanoparticles. Magnetic Fe3O4 nanoparticles (MNP-Fe3O4), a biocompatible and superparamagnetic nanomaterial with satisfactory chemical stability and low toxicity, are widely used as targeted drug carriers with target orientation and sustained-release properties.11–15

In view of this research, we were inspired to explore a drug delivery system for GA based on MNP-Fe3O4 to increase its water solubility and enhance its chemotherapeutic efficiency. To the best of our knowledge, no study to date has been carried out of combination therapy with GA and MNP-Fe3O4 for pancreatic cancer. We have investigated the anticancer efficacy of this combination in pancreatic cancer for the first time. In this study, GA was loaded onto MNP-Fe3O4 (GA-MNP-Fe3O4) as a drug delivery system, and we then identified the cytotoxic effects of GA-MNP-Fe3O4 in Capan-1 pancreatic cancer cells, investigated the apoptosis induced, and further measured the expression of apoptosis-related proteins, including caspase 3, caspase 9, Bax, and Bcl-2, to elucidate the possible mechanisms involved.

Materials and methods
Main chemicals and apparatus
Iron (II) chloride tetrahydrate (FeCl2·4H2O) and iron (III) chloride hexahydrate (FeCl3·6H2O) were obtained from Sinopharm Chemical Reagent Co Ltd (Shanghai, China). Ammonium hydroxide and citric acid were acquired from Shanghai Lingfeng Chemical Reagent Co Ltd (Shanghai, China). GA (Kanion Pharmaceutical Co Ltd, Jiangsu, China) was dissolved in dimethyl sulfoxide (Sigma Aldrich, St Louis, MO), stored at −20°C, and then diluted as needed in RPMI-1640 medium (Gibco/BRL, Carlsbad, CA). Monoclonal antibodies, including caspase 3, Bax, Bcl-2, caspase 9, and β-actin, were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The horseradish peroxidase-conjugated IgG antibody was obtained from Nanjing KeyGen Biotech Inc (Nanjing, China).

Synthesis of magnetic Fe3O4 nanoparticles
Magnetic Fe3O4 nanoparticles were prepared by coprecipitation of Fe (III) and Fe (II) with ammonium hydroxide in a nitrogen environment. In a typical synthetic experiment, FeCl3·6H2O 2.61 g and FeCl2·4H2O 1.04 g were dissolved in 100 mL of deionized water and heated to 80°C, followed by the slow addition of 10 mL of ammonium hydroxide with vigorous stirring for 20 minutes. Black Fe3O4 precipitates were obtained and washed immediately with distilled water five times by magnetic separation. The precipitates were then dispersed in distilled water with 1.25 g citric acid, which acted as a stabilizer of the colloidal nanocrystallites, with vigorous stirring for 90 minutes. The products, ie, citric acid-coated MNP-Fe3O4, were cooled to room temperature and extracted by a magnet. Finally, after being washed with ethanol and finally with deionized water, the products were lyophilized and stored at room temperature.

Preparation of GA-loaded magnetic Fe3O4 nanoparticles
Before being applied in the present experiment, MNP-Fe3O4 were well distributed in RPMI-1640 medium with 10% heated inactivated fetal bovine serum using ultrasound treatment in order to obtain a MNP-Fe3O4 colloidal suspension. As previously reported,16 GA at different concentrations was conjugated with the MNP-Fe3O4 colloidal suspension by mechanical absorption polymerization at 4°C for 48 hours to construct GA-loaded MNP-Fe3O4 (GA- MNP-Fe3O4), which acted as a drug delivery system.

Cell culture
The Capan-1 pancreatic cancer cells, obtained from the Shanghai Institute of Cell Biology, Chinese Academy of Sciences, were cultured in RPMI-1640 supplemented with 10% heat-inactivated fetal bovine serum, 100 U/mL penicillin, and 100 µg/mL streptomycin at 37.0°C in humidified air with 5% CO2. The cells were in log phase prior to the following experiments.
Assay of anticancer activity
The cytotoxicity of MNP-Fe₃O₄, GA, and GA-MNP-Fe₃O₄ was studied against Capan-1 pancreatic cancer cells with MTT assays. Cells at 1 × 10⁵/mL were seeded in 96-well plates and incubated for 24 hours. The growth medium was then replaced with 200 µL of the prepared medium containing free GA and GA-MNP-Fe₃O₄, in which the GA concentration was 0, 0.25, 0.5, 1.0, and 2.0 µmol/L. The cells were also treated by MNP-Fe₃O₄ alone to evaluate cytotoxicity. Cells without any treatment were used as the control group. The cells were further incubated for 48 hours, and the relative anticancer activity was assessed using MTT assays. In brief, MTT solutions were added after the treatments and incubated for an additional 4 hours. Dimethyl sulfoxide was added to solubilize the formazan crystal, and optical density at 492 nm was recorded. The cell viability fraction (%) was calculated as:

\[
\frac{\text{OD}_{492 \text{ nm in test cells}}}{\text{OD}_{492 \text{ nm in control cells}}} \times 100\%
\]

DAPI staining
The cells were treated according to the above methods for 48 hours, and then fixed with 4% polyoxymethylene prior to washing with phosphate-buffered saline. The washed cells were then stained with DAPI 1 mg/mL for 15 minutes in the dark. The staining images were recorded using the fluorescent microscope.

Western blot analysis
After the different treatments, expression of apoptosis-related proteins was detected by Western blot. In brief, total protein was isolated and subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis, and transferred to a polyvinylidene fluoride membrane. After being blocked, the membrane was incubated with primary polyclonal antibodies, either anti-caspase 3, Bax, Bcl-2, caspase 9, or anti-β-actin overnight at 4°C, and subsequently incubated with horseradish peroxidase-conjugated IgG antibody as the secondary antibody for one hour at room temperature. The protein bands were detected by an enhanced ECL detection system (Amersham, UK). After normalization by the corresponding expression of β-actin, protein expression levels of caspase 3, Bax, Bcl-2, and caspase 9 were determined by densitometry scans.

Statistical analysis
All the data are presented as means ± standard deviations. The F-test was used for significance testing, and \( P < 0.05 \) was considered to be statistically significant. All tests were performed using SPSS (v 13.0, SPSS Inc, Chicago, IL).

Results and discussion
Characterization of magnetic Fe₃O₄ nanoparticles
The synthesized MNP-Fe₃O₄ capped with citric acid were characterized by transmission electron microscopy. As shown in Figure 1, MNP-Fe₃O₄ were observed to have a spherical shape, with a diameter of about 20 nm. The size distribution of these MNP-Fe₃O₄ is shown in Figure 2. It has suitable dimensions to escape renal rapid excretion, as well as to avoid components of the reticular endothelial system, thus facilitating potentially passive targeting of drugs to tumors via the enhanced permeation and retention effect and active targeting with target orientation of magnetic field, then increasing the accumulation of drugs in tumor cells after endocytosis.¹⁷

Anticancer activity in vitro
GA exhibits potent anticancer activity in many kinds of cancer cells.⁴⁻⁷ However, whether or not GA induces apoptosis of Capan-1 pancreatic cancer cells, and the molecular mechanisms involved, is not clear. In addition, the therapeutic effect of GA is limited due to low water solubility (<1 µg/mL).⁸ Therefore, we sought to identify the potential benefit of combination therapy using GA-MNP-Fe₃O₄ as a drug carrier for pancreatic cancer and whether MNP-Fe₃O₄ could promote the apoptosis induced by GA. In our study, no precipitation of GA was noted in the colloidal suspension of the GA-MNP-Fe₃O₄ drug delivery system after 2 months of storage, which indicates that the solubility of GA was improved and drug delivery was stable during storage at 4°C. To explore the anticancer efficiency of the GA-MNP-Fe₃O₄ drug delivery...
system, we cultured Capan-1 pancreatic cancer cells with free GA at different concentrations (0, 0.25, 0.5, 1.0, and 2.0 µmol/L), MNP-Fe₃O₄ loading GA with equivalent GA concentration for 48 hours. The cytotoxicity results were estimated by MTT assay and are shown in Figure 3. Cytotoxicity testing of a nanomaterial is the first-level evaluation before its biomedical application. When treated by MNP-Fe₃O₄ 20 µg/mL, about 95% of the cells survived (Figure 3, pink line), which is consistent with our previous report.11–16 The results suggested that the MNP-Fe₃O₄ capped with citric acid synthesized in this study lack cytotoxicity, thus ensuring a wide potential range of applications in the field of biomedical science and cancer therapy. Compared with GA alone (Figure 3, red line), the viability of Capan-1 pancreatic cancer cells treated by GA-MNP-Fe₃O₄ obviously decreased (Figure 3, green line). Meanwhile, our results also indicate that lethality increased with increasing concentrations of GA, suggesting a dose-dependent effect in vitro. The increased cytotoxicity may be due to improved GA cellular uptake by the GA-MNP-Fe₃O₄ drug delivery system, which increases the water solubility of GA through the endocytosis pathway and then induces release of GA from the MNP-Fe₃O₄ to promote efficient cell killing, which is a common characteristic of nanoparticle-based drug delivery systems.18,19

In addition, as shown in the insets of Figure 3, the optical microscopic observations confirm the MTT results. The Capan-1 pancreatic cancer cells without any treatment attached to the plate with a normal elongated shape. Notably, the cells treated with MNP-Fe₃O₄ showed no morphological changes. If these cells are in a lethal state, they detach from the plate and assume a smaller and spherical morphology. It is obvious that GA and GA-MNP-Fe₃O₄ would cause more significant morphological changes, indicating the increasing probability of cell death, and the GA-MNP-Fe₃O₄ group was even more effective. Cooperation of MNP-Fe₃O₄ and GA could kill even more cancer cells, indicating their synergistic anticancer activity.

Figure 2 Size distribution histogram of magnetic Fe₃O₄ nanoparticles.

Figure 3 Cytotoxic effect of GA or GA-loaded MNP-Fe₃O₄ against the Capan-1 pancreatic cancer cells. Inset: Microscopic images of the Capan-1 cells after different treatments for 48 hours. (A) untreated cells as control, (B) MNP-Fe₃O₄, (C) GA alone, and (D) GA-loaded MNP-Fe₃O₄.

Notes: The concentrations of GA, MNP-Fe₃O₄ are 1 µmol/L and 20 µg/mL, respectively. Data are expressed as means ± standard deviations (n = 3).

Abbreviations: GA, gambogic acid; MNP-Fe₃O₄, magnetic Fe₃O₄ nanoparticles.
Morphologic characterization of apoptosis

Apoptosis is an important metabolic step in regulating the number and growth of cells. If apoptosis is blocked, metabolism becomes disordered, and tumors develop and grow. Most anticancer agents exert their anticancer effects by inducing apoptosis. Recently, MNP-Fe₃O₄ have been widely used as targeted drug carriers to enhance the efficiency of anticancer drug delivery based on an ability for target orientation and sustained-release properties. Our previous studies have demonstrated the synergistic effect between MNP-Fe₃O₄ and anticancer drugs in terms of intracellular accumulation in cancer cells to induce apoptosis.

Nuclear DAPI staining was performed in the present study to explore the mechanism of the distinct improvement in anticancer activity induced by synergism between MNP-Fe₃O₄ and GA. To confirm the existence of apoptosis, a study of the morphological changes in the cells was undertaken. Evaluation of normal or apoptotic cells depends on their morphological characterization. Normal nuclei (smooth nuclear) and apoptotic nuclei (condensed or fragmented chromatin) are easily distinguished. As shown in Figure 4, the nuclear morphology analysis showed characteristic apoptotic changes, such as chromatin condensation, convoluted nuclei with cavitations, fragmentation of the nucleus, and apoptotic bodies in the Capan-1 pancreatic cancer cells after treatment with both GA and GA-MNP-Fe₃O₄. There was almost no evidence of apoptosis in the control group (Figure 4A) and in the MNP-Fe₃O₄ group (Figure 4B). When the cells were treated with GA-MNP-Fe₃O₄ (Figure 4D), typical apoptotic morphology was more apparent than in cells treated with GA alone (Figure 4C). These findings strongly indicate that the synergistic effect of MNP-Fe₃O₄ and GA killed the cancer cells by inducing apoptosis rather than necrosis.

Expression of Bax, Bcl-2, caspase 9, and caspase 3 proteins

Next, we studied the molecular mechanism of apoptosis induced by the synergistic effect of MNP-Fe₃O₄ and GA in Capan-1 pancreatic cancer cells. The antiapoptotic protein, Bcl-2, has been associated with inhibition of apoptosis and cell survival mechanisms. The Bax protein is a proapoptotic member of this family, and its increased expression is often associated with increased apoptosis in target cells. Apoptosis is the consequence of a series of precisely regulated events that are frequently altered in tumor cells. In general, the sequence of events has been broadly categorized into two pathways, ie, the extrinsic pathway, which involves activation of the tumor necrosis factor/Fas death receptor family, and the intrinsic pathway, which involves the mitochondria. In both pathways, an apoptotic death stimulus results in activation of caspases, the major executioners in this process, either directly or via activation of the mitochondrial death program. Therefore, we examined changes in the expression levels of apoptosis-regulating proteins, including caspase 3, caspase 9, Bax, and Bcl-2, by Western blot to explore possible signaling pathways through which GA-MNP-Fe₃O₄ induced distinct improvement in anticancer activity. As shown in Figure 5, when the Capan-1 pancreatic cancer cells were treated with GA and GA-MNP-Fe₃O₄ for 48 hours, levels of caspase 3, caspase 9, Bax, and Bcl-2 were significantly upregulated compared with the control group. Meanwhile, upregulated levels in the GA-MNP-Fe₃O₄ group were slightly higher than those in the GA group (P < 0.05). However, they were not obviously altered when the cells were treated with MNP-Fe₃O₄ alone (P > 0.05). In contrast, compared with the control group, the levels of Bcl-2 protein in cells treated with GA and GA-MNP-Fe₃O₄ were both significantly downregulated. Furthermore, the level of Bcl-2 in the GA-MNP-Fe₃O₄ group was lower than that in GA group, and was also not obviously altered when the cells were
treated with MNP-Fe₃O₄ alone (P > 0.05). In our study, the ratio of Bax/Bcl-2 protein expression increased dramatically when the Capan-1 pancreatic cancer cells were treated with GA-MNP-Fe₃O₄. A large amount of evidence has shown that the sensitivity of cells to the apoptotic stimulus is determined by the relative ratio of proapoptotic and antiapoptotic members of the Bcl-2 family, ie, the mitochondrial-related death switch.22 We deduce that upregulated Bax leads to disruption of the integrity of the mitochondrial membrane and promotes release of cytochrome c from the mitochondria, resulting in caspase 9/caspase 3 activation and DNA fragmentation. Caspase activation is generally considered to be a hallmark of apoptosis, and caspase 3 is the main effector caspase that is involved in apoptosis.23 Thus, the ratio of Bcl-2/Bax might be a critical factor in the cell threshold for undergoing apoptosis induced by GA-MNP-Fe₃O₄. Collectively, GA combined with MNP-Fe₃O₄ has been shown to elevate the Bax/Bcl-2 ratio dramatically, enhance caspase 9/caspase 3 activity, and further stimulate the initiation of mitochondrial apoptosis signaling.

Based on the above studies, Figure 6 schematically illustrates the possible processes by which the GA-MNP-Fe₃O₄ drug delivery system induces a distinct improvement in anticancer activity. Firstly, GA was conjugated with the MNP-Fe₃O₄ colloidal suspension by mechanical absorption polymerization to construct GA-MNP-Fe₃O₄, which acted as a drug delivery system. This drug delivery system increased the water solubility of GA and enhanced its chemotherapeutic efficiency after endocytosis, and so has tremendous potential for application in cancer therapy by inducing apoptosis, a preferred mode for killing cancer cells in cancer therapy, and is induced synergistically, resulting in a distinct improvement in anticancer activity.

**Conclusion**

A GA-MNP-Fe₃O₄ drug delivery system was developed to increase the water solubility of GA and enhance its chemotherapeutic efficiency. MNP-Fe₃O₄ enhanced the anticancer activity of GA in Capan-1 pancreatic cancer cells by inducing apoptosis, and the synergistic effect may be due to regulation of various antiapoptotic and proapoptotic gene products, including Bax, Bcl-2, caspase 9, and caspase 3. All these characteristics demonstrate that combination therapy with GA and MNP-Fe₃O₄ represents a promising strategy in the treatment of pancreatic cancer.

**Acknowledgment**

This work was supported by the National Key Basic Research Program (2010CB732404) and the National Nature Science Foundation of China (30740062, 30872970).

**Disclosure**

The authors report no conflicts of interest in this work.
References

1. Tempero MA, Berlin J, Ducreux M, et al. Pancreatic cancer treatment and research: An international expert panel discussion. Ann Oncol. 2011;22:1500–1506.
2. Jemal A, Siegel R, Xu JQ, Ward E. Cancer Statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
3. Nakai Y, Isayama H, Sasaki T, et al. Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy. Crit Rev Oncol Hematol. 2011;78:252–259.
4. Guo QL, You QD, Yuan ST, Zhao L. General gambogic acids inhibited growth of human hepatoma SMMC-7721 cells in vitro and in nude mice. Acta Pharmacol Sin. 2004;25:769–774.
5. Yu J, Guo QL, You QD, et al. Gambogic acid-induced G(2)/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells. Carcinogenesis. 2007;28:632–638.
6. Kasibhatla S, Jessen KA, Maliartchouk S, et al. A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid. Proc Natl Acad Sci U S A. 2005;102:12095–12100.
7. Wu QZ, Guo QL, You QD, Zhao L, Gu HY. Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol Pharm Bull. 2004;27:1769–1774.
8. Zhu X, Zhang C, Wu XL, et al. Preparation, physical properties, and stability of gambogic acid-loaded micelles based on chitosan derivatives. Drug Dev Ind Pharm. 2008;34:2–9.
9. Wang QJ, Sui MH, Fan WM. Nanoparticles for tumor targeted therapies and their pharmacokinetics. Curr Drug Metab. 2010;11:129–141.
10. Zhang HJ, Chen BA, Jiang H, Wang CL, Wang HP, Wang XM. A strategy for ZnO nanorod mediated multi-mode cancer treatment. Biomaterials. 2011;32:190–1914.
11. Chen BA, Cheng J, Shen MF, et al. Magnetic nanoparticle of Fe3O4 and 5-bromotetrandrin interact synergistically to induce apoptosis by daunorubicin in leukemia cells. Int J Nanomedicine. 2009;4:65–71.
12. Chen BA, Mao PP, Cheng J, et al. Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizing daunorubicin and MDR1 shRNA expression vector in leukemia cells. Int J Nanomedicine. 2010;5:437–444.
13. Wu WW, Chen BA, Cheng J, et al. Biocompatibility of Fe3O4/DNR magnetic nanoparticles in the treatment of hematologic malignancies. Int J Nanomedicine. 2010;5:1079–1084.
14. Wang J, Chen BA, Cheng J, et al. Apoptotic mechanism of human leukemia K562/A02 cells induced by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin. Int J Nanomedicine. 2011;6:1027–1034.
15. Wang J, Chen BA, Cheng J, et al. Synthesis and antitumor efficacy of daunorubicin-loaded magnetic nanoparticles. Int J Nanomedicine. 2011;6:203–211.
16. Chen BA, Liang YQ, Wu WW, et al. Synergistic effect of magnetic nanoparticles of Fe3O4 with gambogic acid on apoptosis of K562 leukemia cells. Int J Nanomedicine. 2009;4:251–259.
17. Zhang DW, Zhang H, Nie J, Yang J. Synthesis and self-assembly behavior of pH-responsive amphiphilic copolymers containing ketal functional groups. Polym Int. 2010;59:967–974.
18. Barea LA, Swaan PW. Endocytic mechanisms for targeted drug delivery. Adv Drug Delivery Rev. 2007;59:748–758.
19. Yoo HS, Lee KH, Oh JE, Park TG. In vitro and in vivo antitumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J Control Release. 2000;68:419–431.
20. Lin BL, Shen XD, Cui S. Application of nanosized Fe3O4 in anticancer drug carriers with target-orientation and sustained-release properties. Biomed Mater. 2007;2:132–134.
21. Fecker LF, Geilen CC, Tchernev G, et al. Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. J Invest Dermatol. 2006;126:1366–1371.
22. Yang E, Korsmeyer SJ. Molecular thanatopsis: A discourse on the BCL2 family and cell death. Blood. 1996;88:386–401.
23. Ghavami S, Hashemi M, Ande SRS, et al. Apoptosis and cancer: Mutations within caspase genes. J Med Genet. 2009;46:497–510.

International Journal of Nanomedicine

Publish your work in this journal

The International Journal of Nanomedicine is an international, peer-reviewed journal focusing on the application of nanotechnology in diagnostics, therapeutics, and drug delivery systems throughout the biomedical field. This journal is indexed on PubMed Central, MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, Journal Citation Reports/Science Edition, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal